Using Neuroimaging to Early Diagnose Alzheimer's Disease Through Hippocampal Atrophy Assessment

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

85 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-11-24

Study Completion Date

2023-05-24

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study aims to better understand Alzheimer's disease by looking at brain scans, specifically MRI images, to detect early signs of brain changes linked to the disease. Researchers are focusing on the hippocampus, a part of the brain that shrinks in people with Alzheimer's. The study will also explore other brain changes that often happen alongside hippocampal shrinkage. By analyzing these brain images, the study hopes to find ways to diagnose Alzheimer's earlier and more accurately using advanced imaging techniques.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Evaluation of Age- and Alzheimer's Disease-Related Memory Disorder

NCT00029120

Alzheimer Disease Dementia Memory Disorder +1 more

COMPLETED

A Non-drug Methods Study in Participants With Alzheimer's Disease

NCT01459016

Alzheimer's Disease

COMPLETED PHASE1

Early Diagnosis of Alzheimer's Disease: Clinical, Neuropsychological and Neuroimaging Follow-up of a Cohort of Patients With an Isolated Memory Impairment

NCT00684281

Alzheimer's Disease

COMPLETED NA

MRI of Alzheimer's Disease Imaging Amyloid Plaques in Persons With and Without Memory Problems

NCT00413621

Alzheimer's Disease

COMPLETED

Can the Assessment of the Subhippocampal Region Contribute to the Detection of Early Diagnosis of Alzheimer's Disease? A Validation Study Using PET With Florbetapir (AV-45).

NCT01746706

Alzheimer's Disease

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Alzheimer's Disease Hippocampus Brain Atrophy Magnetic Resonance Imaging Leukoaraiosis Neurodegenerative Diseases Cortical and Subcortical Atrophy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Alzheimer Group

Alzheimer's patients

No interventions assigned to this group

Control Group

Unreached witnesses

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients who underwent a brain MRI (3D T1 Bravo and Cube FLAIR sequences) between January 2018 and June 2022.
* Diagnosis of Alzheimer's disease (for the Alzheimer group).
* No neurological disease for control group participants.
* Complete clinical and biological assessments available.
* Quality imaging without motion artifacts.

Exclusion Criteria

* Incomplete clinical or radiological data.
* Poor image quality (e.g., motion artifacts).
* Presence of other neurodegenerative or psychiatric disorders.

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes